QNCX Earnings
Latest RevenueN/A
Latest Net Income35.9M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q1 2026 | $72.00 | — | 35.9M | — | +205.3% |
| Q4 2025 | -$152.00 | — | -39458000 | — | -171.4% |
| Q3 2025 | -$50.00 | — | -13442000 | — | -92.3% |
| Q2 2025 | -$68.00 | — | -16049000 | — | +46.9% |
| Q1 2025 | -$68.40 | — | -15030000 | — | -31.5% |
| Q4 2024 | -$56.00 | — | -12458000 | — | -33.3% |
| Q3 2024 | -$26.00 | — | -5492000 | — | +13.3% |
| Q2 2024 | -$128.00 | — | -27729000 | — | -357.1% |
| Q1 2024 | -$52.00 | — | -11149000 | — | — |
| Q4 2023 | -$42.00 | — | -8894000 | — | — |
| Q3 2023 | -$30.00 | — | -5351000 | — | — |
| Q2 2023 | -$28.00 | — | -4886000 | — | — |
Quince Therapeutics (QNCX) — Earnings